We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of KIAA1009, encoded by KIAA1009 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, KIAA1009 expression was correlated with distant metastasis-free survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. KIAA1009 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.